WallStSmart

Balchem Corporation (BCPC)vsEcolab Inc (ECL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ecolab Inc generates 1451% more annual revenue ($16.08B vs $1.04B). BCPC leads profitability with a 14.9% profit margin vs 12.9%. ECL appears more attractively valued with a PEG of 2.73. ECL earns a higher WallStSmart Score of 55/100 (C-).

BCPC

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 7.0Value: 5.3Quality: 9.0
Piotroski: 6/9Altman Z: 3.85

ECL

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 6.5Value: 4.7Quality: 5.8
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BCPCOvervalued (-9.1%)

Margin of Safety

-9.1%

Fair Value

$163.78

Current Price

$166.96

$3.18 premium

UndervaluedFair: $163.78Overvalued
ECLSignificantly Overvalued (-142.8%)

Margin of Safety

-142.8%

Fair Value

$125.04

Current Price

$268.54

$143.50 premium

UndervaluedFair: $125.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BCPC2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.8510/10

Safe zone — low bankruptcy risk

ECL3 strengths · Avg: 8.7/10
Market CapQuality
$74.91B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Revenue GrowthGrowth
17.8%8/10

17.8% revenue growth

Areas to Watch

BCPC2 concerns · Avg: 3.0/10
P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
3.792/10

Expensive relative to growth rate

ECL4 concerns · Avg: 3.3/10
P/E RatioValuation
36.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.732/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BCPC

The strongest argument for BCPC centers on Debt/Equity, Altman Z-Score.

Bull Case : ECL

The strongest argument for ECL centers on Market Cap, Return on Equity, Revenue Growth. Revenue growth of 17.8% demonstrates continued momentum.

Bear Case : BCPC

The primary concerns for BCPC are P/E Ratio, PEG Ratio.

Bear Case : ECL

The primary concerns for ECL are P/E Ratio, Price/Book, Piotroski F-Score.

Key Dynamics to Monitor

BCPC profiles as a value stock while ECL is a growth play — different risk/reward profiles.

ECL carries more volatility with a beta of 0.98 — expect wider price swings.

ECL is growing revenue faster at 17.8% — sustainability is the question.

ECL generates stronger free cash flow (758M), providing more financial flexibility.

Bottom Line

ECL scores higher overall (55/100 vs 52/100) and 17.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Balchem Corporation

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Balchem Corporation develops, manufactures, and markets specialty ingredients and performance products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. The company is headquartered in New Hampton, New York.

Ecolab Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.

Want to dig deeper into these stocks?